INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming Deadlines - AZN

Core Viewpoint - AstraZeneca PLC is under investigation for potential securities fraud and unlawful business practices, with implications for its senior executives [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca, focusing on possible securities fraud or unlawful business practices by the company and its executives [1]. - A fraud investigation into AstraZeneca has expanded to include several Chinese government agencies, implicating numerous senior executives [2]. Group 2: Market Reaction - Following the news of the fraud investigation, AstraZeneca's American depositary receipt (ADR) price dropped by $5.16, or 7.22%, closing at $66.27 per ADR on November 5, 2024 [2]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].